List view / Grid view




Bonesupport enrols first patient in injectable bone graft substitute trial

22 May 2017 | By Niamh Marriott, Junior Editor

Bonesupport, the Scandinavian medical technology company, has enrolled their first patient at the University of Texas Health Science Center at San Antonio into the company’s pivotal Investigational Device Exemption (IDE) trial. Cerament G is an injectable antibiotic-eluting bone graft substitute that has proven remodelling capabilities and provides local sustained delivery…


FDA approves IDE study for bone graft substitute, Cerament G

10 August 2016 | By Niamh Louise Marriott, Digital Content Producer

Bonesupport’s Fortify study will evaluate the safety and efficacy of Cerament G as part of surgical repair of open diaphyseal tibial fractures. The trial will enrol up to 230 patients at up to 30 centres globally, with the aim of having at least 50% of the study data coming from…